4.3 Article

Histopathological Growth Pattern, Proteolysis and Angiogenesis in Chemonaive Patients Resected forMultiple Colorectal LiverMetastases

期刊

JOURNAL OF ONCOLOGY
卷 2012, 期 -, 页码 -

出版社

HINDAWI LTD
DOI: 10.1155/2012/907971

关键词

-

类别

资金

  1. Oncological Research Fund of Rigshospitalet
  2. Roche
  3. Danish Cancer Research Foundation
  4. Capital Region of Denmark Research Foundation
  5. European Community's Seventh Framework Programme [201279]
  6. J. Christensen and K. Christensens Fund
  7. Hede Nielsens Foundation
  8. Erichsens Memorial Foundation
  9. born la Cour-Holmens Foundation
  10. Keystone Scholarship

向作者/读者索取更多资源

The purpose of this study was to characterise growth patterns, proteolysis, and angiogenesis in colorectal liver metastases from chemonaive patients with multiple liver metastases. Twenty-four patients were included in the study, resected for a median of 2.6 metastases. The growth pattern distribution was 25.8% desmoplastic, 33.9% pushing, and 21% replacement. In 20 patients, identical growth patterns were detected in all metastases, but in 8 of these patients, a second growth pattern was also present in one or two of the metastases. In the remaining 4 patients, no general growth pattern was observed, although none of the liver metastases included more than two growth patterns. Overall, a mixed growth pattern was demonstrated in 19.3% of the liver metastases. Compared to metastases with pushing, those with desmoplastic growth pattern had a significantly up-regulated expression of urokinase-type plasminogen activator receptor (P = 0.0008). Angiogenesis was most pronounced in metastases with a pushing growth pattern in comparison to those with desmoplastic (P = 0.0007) and replacement growth pattern (P = 0.021). Although a minor fraction of the patients harboured metastases with different growth patterns, we observed a tendency toward growth pattern uniformity in the liver metastases arising in the same patient. The result suggests that the growth pattern of liver metastases is not a random phenomenon.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases

Boram Ham, Ni Wang, Zarina D'Costa, Maria Celia Fernandez, France Bourdeau, Patrick Auguste, Martin Illemann, Rikke Loevendahl Eefsen, Gunilla Hoyer-Hansen, Ben Vainer, Maximilien Evrard, Zu-Hua Gao, Pnina Brodt

CANCER RESEARCH (2015)

Article Oncology

The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study

Hans Christian Rolff, Ib Jarle Christensen, Ben Vainer, Lars Bo Svendsen, Rikke Lovendahl Eefsen, Michael Wilhelmsen, Ida Katrine Lund, Gunilla Hoyer-Hansen, Hans Jorgen Nielsen, Martin Illemann

CLINICAL CANCER RESEARCH (2016)

Article Oncology

Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab

Rikke Lovendahl Eefsen, Lars Engelholm, Gro L. Willemoe, Gert G. Van den Eynden, Ole Didrik Laerum, Ib Jarle Christensen, Hans Christian Rolff, Gunilla Hoyer-Hansen, Kell Osterlind, Ben Vainer, Martin Illemann

INTERNATIONAL JOURNAL OF CANCER (2016)

Article Biochemistry & Molecular Biology

Tissue Inhibitor of Matrix Metalloproteinase-1 Expression in Colorectal Cancer Liver Metastases is Associated With Vascular Structures

Martin Illemann, Rikke Helene Lovendahl Eefsen, Nigel Charles Bird, Ali Majeed, Kell Osterlind, Ole Didrik Laerum, Warner Alpizar-Alpizar, Ida Katrine Lund, Gunilla Hoyer-Hansen

MOLECULAR CARCINOGENESIS (2016)

Article Oncology

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine

I. Kumler, R. L. Eefsen, Peter Grundtvig Sorensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)

Article Oncology

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

S. Ehmsen, L. H. Jakobsen, M. E. Lendorf, R. L. Eefsen, L. Bentsen, A. S. Knoop, N. Aggerholm-Pedersen, H. Skuladottir, J. Herrstedt, L. H. Jensen, C. Rotbol, M. B. Damm, K. Wedervang, A. Glenthoj, J. Ryg, H. Frederiksen, A. R. Kodahl

Summary: This nationwide prospective study found that age and comorbidities are associated with adverse outcomes of SARS-CoV-2 infection in cancer patients, especially those with progressive disease being at a greater risk of fatal outcomes from COVID-19.

ACTA ONCOLOGICA (2021)

Meeting Abstract Oncology

Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)

A. H. Awada, M. Zematis, S. Ochsenreither, R. L. Eefsen, D. Arnold, S. Cicenas, J. Yachnin, P. Pfeiffer, L. Paz-Ares, C. Jungels, R. Greil, L. Ostergaard Poulsen, E. Van Cutsem, I. Garcia Ribas, L. Thorsson, J. J. Collignon

ANNALS OF ONCOLOGY (2021)

Meeting Abstract Oncology

COLAR: Results from an intervention study investigating IL-6 blockade with tocilizumab for treatment of immune checkpoint inhibitor induced colitis and arthritis

R. B. Holmstrom, O. H. Nielsen, S. Jacobsen, L. B. Riis, S. Theile, J. T. Bjerrum, P. Vilmann, J. S. Johansen, M. K. Boisen, R. L. Eefsen, I. M. Svane, D. Nielsen, I. M. Chen

ANNALS OF ONCOLOGY (2021)

Meeting Abstract Oncology

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

Ahmad Awada, Sebastian Ochsenreither, Rikke Loevendahl Eefsen, Dirk Arnold, Jeffrey Yachnin, Per Pfeiffer, Christiane Jungels, Richard Greil, Laurids Poulsen, Eric Van Cutsem, Lars Thorsson, Christer Svedman, Ignacio Garcia-Ribas, Joelle Collignon

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Genomic landscape of treatment refractory metastatic colorectal cancer

R. L. Eefsen, K. S. Simonsen, P. Grundtvig, L. Klarskov, I. M. Chen, D. Hogdall, B. Jensen, T. Lorentzen, T. S. Poulsen, S. Theile, D. Nielsen, E. Hogdall

Summary: In this retrospective analysis, 90% of patients with treatment-refractory mCRC had cancer driver mutations identified through genomic sequencing, but only 2.5% of patients received targeted therapy that matched their mutations. The study highlights the challenge of limited targeted treatment options for mCRC patients with cancer driver mutations.

ACTA ONCOLOGICA (2021)

Article Oncology

Therapy with pembrolizumab in treatment-naive patients with nonmetastatic, mismatch repair deficient colorectal cancer

Rikke Lovendahl Eefsen, Jim S. S. Larsen, Louise L. L. Klarskov, Rahim Altaf, Estrid Hogdall, Peter Ingeholm, Jakob Lykke, Dorte L. L. Nielsen, Per Pfeiffer, Laurids O. Poulsen, Camilla Qvortrup, Jakob V. V. Schou, Morten Mau-Sorensen, Kell Osterlind, Benny V. V. Jensen

Summary: Therapy with immune checkpoint inhibitors has shown effectiveness in patients with metastatic mismatch-repair deficient colorectal cancer. However, the data on neoadjuvant ICI treatment in locally advanced CRC patients are limited. A study in Danish oncological centers evaluated the use of preoperative pembrolizumab in 10 treatment-naive dMMR CRC patients, demonstrating feasibility and effectiveness.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Medicine, General & Internal

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Nicklas Juel Spindler, Gitte Fredberg Persson, Susann Theile, Dorte Lisbeth Nielsen, Estrid Hogdall, Gina Al-Farra, Helle Westergren Hendel, Torben Lorentzen, Inge Marie Svane, Henriette Lindberg, Rikke Lovendahl Eefsen

Summary: This study aims to investigate the efficacy of combining SBRT and CPI treatment in patients with mCRPC. A total of 80 evaluable patients who have progressed after multiple lines of treatment will be enrolled and receive ipilimumab and nivolumab combination therapy, with some patients also receiving SBRT. The primary endpoints are objective response rate and PSA response rate, and secondary endpoints include safety, radiographic progression-free survival, clinical benefit rate, duration of response, PSA-progression-free survival beyond 12 weeks, quality of life, and overall survival. The results will be published in an international peer-reviewed journal.

BMJ OPEN (2023)

Article Oncology

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Tina Kringelbach, Martin Hojgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harslof, Laila Belcaid, Julie Gehl, Lise Sondergaard, Rikke Lovendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen

Summary: The ProTarget trial aims to investigate the anti-tumor activity and toxicity of commercially available targeted therapies in cancer patients with specific actionable genomic alterations. This national trial will provide new data and insights into molecular pathways and potentially expand personalized cancer treatment strategies.

BMC CANCER (2023)

Meeting Abstract Oncology

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Eric Van Cutsem, Rikke Lovendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Dirk Arnold, Edita Baltruskeviciene, Per Pfeiffer, Jeffrey Yachnin, Rocio Garcia Carbonero, Richard Greil, Christiane Jungels, Laurids Poulsen, Ahmad Awada, Ignacio Garcia Ribas, Nedjad Losic, Joelle Collignon

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

Pieter-Jan van Dam, Eric P. van der Stok, Laure-Anne Teuwen, Gert G. Van den Eynden, Martin Illemann, Sophia Frentzas, Ali W. Majeed, Rikke L. Eefsen, Robert R. J. Coebergh van den Braak, Anthoula Lazaris, Maria Celia Fernandez, Boris Galjart, Ole Didrik Laerum, Roni Rayes, Dirk J. Grunhagen, Michelle Van de Paer, Yves Sucaet, Hardeep Singh Mudhar, Michael Schvimer, Hanna Nystrom, Mark Kockx, Nigel C. Bird, Fernando Vidal-Vanaclocha, Peter Metrakos, Eve Simoneau, Cornelis Verhoef, Luc Y. Dirix, Steven Van Laere, Zu-hua Gao, Pnina Brodt, Andrew R. Reynolds, Peter B. Vermeulen

BRITISH JOURNAL OF CANCER (2017)

暂无数据